Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,548 | 2,628 | 15:50 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.11. | HANSA BIOPHARMA AB: Hansa Biopharma to Attend Jefferies London Healthcare Conference | 3 | Cision News | ||
30.10. | Hansa Biopharma AB: Hansa Biopharma to Attend Truist Securities BioPharma Symposium | 192 | PR Newswire | LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York... ► Artikel lesen | |
18.10. | Telefonkonferenz zu Quartalszahlen: Hansa Biopharma meldet Rekordumsatz für IDEFIRIX im dritten Quartal 2024 | 2 | Investing.com Deutsch | ||
18.10. | Earnings call: Hansa Biopharma reports record IDEFIRIX sales in Q3 2024 | 2 | Investing.com | ||
17.10. | Hansa Biopharma Q3 GAAP EPS of -SEK 1.53, revenue of SEK78.4M | 1 | Seeking Alpha | ||
HANSA BIOPHARMA Aktie jetzt für 0€ handeln | |||||
17.10. | Hansa Biopharma AB: Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results | 174 | PR Newswire | Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance
LUND, Sweden, Oct. 17, 2024 /PRNewswire/ -- Hansa Biopharma... ► Artikel lesen | |
07.10. | Hansa Biopharma AB: Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial | 190 | PR Newswire | LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ STOCKHOLM: HNSA), today announced positive results from a 12-month follow up analysis from... ► Artikel lesen | |
03.10. | HANSA BIOPHARMA AB: Hansa Biopharma to host Q3 2024 interim results conference call | 9 | Cision News | ||
05.09. | Hansa Biopharma AB: Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference | 216 | PR Newswire | LUND, Sweden, Sept. 5, 2024 /PRNewswire/ -- Hansa Biopharma today announced that Søren Tulstrup will participate in a Fireside chat hosted by Douglas Tsao, Managing Director and Senior Financial... ► Artikel lesen | |
23.08. | Hansa Biopharma AB: Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis | 815 | PR Newswire | LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US... ► Artikel lesen | |
22.07. | Earnings call: Hansa Biopharma reports solid Q2 with growth in Idefirix sales | 3 | Investing.com | ||
18.07. | Hansa Biopharma Q2 GAAP EPS of -SEK3.30 | 1 | Seeking Alpha | ||
18.07. | Hansa Biopharma AB: Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update | 473 | PR Newswire | LUND, Sweden, July 18, 2024 /PRNewswire/ -- Hansa Biopharma today announced its first half and second quarter 2024 financial results and business update.
Søren Tulstrup, President and... ► Artikel lesen | |
03.07. | Hansa Biopharma AB: Hansa Biopharma to host Q2 2024 interim results conference call | 294 | PR Newswire | LUND, Sweden, July 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may... ► Artikel lesen | |
28.06. | Hansa Biopharma AB: Hansa Biopharma: increase in number of shares and votes | 702 | PR Newswire | LUND, Sweden, June 28, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital... ► Artikel lesen | |
27.06. | Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ) | 1 | Cision News | ||
07.06. | HANSA BIOPHARMA AB: Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm | 5 | Cision News | ||
31.05. | Hansa Biopharma AB: Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial | 810 | PR Newswire | LUND, Sweden, May 31, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (NASDAQ Stockholm: HNSA), today announced recruitment and randomization in its US ConfIdeS trial... ► Artikel lesen | |
27.05. | Notice to Annual General Meeting in Hansa Biopharma AB (publ) | 4 | Cision News | ||
21.05. | Hansa Biopharma AB: Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting | 260 | PR Newswire | LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 97,40 | -0,20 % | BioNTech-Aktie: Was bringt diese Übernahme? | Die BioNTech-Aktie hat am Mittwoch um fast +5% auf 111,48 US$ zugelegt, nachdem die Mainzer eine insgesamt fast eine Milliarde US$ schwere Übernahme bekannt gegeben haben. Was steckt hinter diesem Deal?... ► Artikel lesen | |
EVOTEC | 9,870 | -0,35 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
CUREVAC | 2,328 | -2,02 % | CureVac mit BRANDNEUER Prognose: Steht die Aktie jetzt vor einem Kursdebakel - Sofortiges HANDELN erforderlich! | ||
MODERNA | 34,880 | -0,48 % | Opening Bell: Disney, Boeing, Moderna, Alibaba, Netease, Axon Enterprise, Applied Materials, Micron | Die Wall Street präsentierte sich gestern recht energielos. Der Dow Jones verzeichnete einen Verlust von 0,47 Prozent, der Nasdaq 100 gab 0,63 Prozent ab. Bei den Einzelthemen geht es heute um Disney... ► Artikel lesen | |
NOVAVAX | 7,702 | +0,64 % | AKTIEN IM FOKUS: Impfstoffwerte unter Druck - Trump nominiert Skeptiker | FRANKFURT/NEW YORK (dpa-AFX) - Europäische und US-amerikanische Impfstoff-Aktien haben mit deutlichen Kursverlusten auf die Nominierung des Impfskeptikers Robert F. Kennedy Jr. als US-Gesundheitsminister... ► Artikel lesen | |
HEIDELBERG PHARMA | 2,210 | -2,64 % | Heidelberg Pharma Aktie: Bedeutung der jüngsten Entwicklungen | Die Heidelberg Pharma AG, ein führendes Unternehmen in der Entwicklung von Antikörper-Wirkstoff-Konjugaten (ADCs) für die Krebstherapie, verzeichnet aktuell eine leichte Kursschwäche. Der letzte Kurs... ► Artikel lesen | |
4SC | 4,800 | -8,75 % | 4SC: Bis in das erste Quartal 2026 hinein finanziert | 4SC hat Eckdaten für den Stichtag 30. September 2024 gemeldet. In den ersten neun Monaten habe es im Durchschnitt operativ einen Mittelabfluss von 0,6 Millionen Euro pro Monat gegeben. Dies liegt am... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 3,790 | +0,40 % | Inovio Pharmaceuticals Inc. Q3 Loss Narrows | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) reported Loss for third quarter that decreased from last yearThe company's earnings totaled -$25.17 million, or -$0.89 per share. This... ► Artikel lesen | |
INFLARX | 1,850 | -4,88 % | InflaRx N.V.: InflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome | JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability | DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
DYNAVAX | 11,235 | -2,77 % | Dynavax Technologies: Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates | HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth
Hepatitis B adult vaccine market expected to expand to a peak... ► Artikel lesen | |
BIOMARIN PHARMACEUTICAL | 59,10 | +1,62 % | BioMarin: Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced positive and consistent results from multiple real-world evidence studies of VOXZOGO (vosoritide) in children with achondroplasia.... ► Artikel lesen | |
IDEXX LABORATORIES | 380,00 | -4,31 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 19.11.2024 | The following instruments on XETRA do have their last trading day on 19.11.2024.Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 19.11.2024.ISIN NameUS0010841023 AGCO Corp.US45168D1046 IDEXX... ► Artikel lesen | |
VAXART | 0,575 | -0,52 % | Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary |